Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Destiny Pharma Ltd (AIM: DEST) is a clinical-stage biotechnology company dedicated to the development of novel medicines that can prevent and treat life-threatening infections. Their pipeline is focused on innovative anti-microbial drugs designed to address the global problem of antimicrobial resistance (AMR). Key development programs include XF-73 Nasal gel for the prevention of post-surgical staphylococcal infections and NTCD-M3 for the prevention of C. difficile infection recurrence. The company leverages its proprietary XF drug platform.
The headquarters serves as the central hub for corporate strategy, research and development program management, clinical operations oversight, financial management, and investor relations.
Located within the Sussex Innovation Centre, providing access to modern facilities, networking opportunities, and a supportive environment for innovative companies. The Centre itself is designed to foster collaboration and growth.
Destiny Pharma fosters a science-driven, innovative, and collaborative work culture. Employees are typically highly specialized, working in a focused environment aimed at advancing novel therapeutics through clinical development.
Its location within a university-affiliated science park allows for potential collaborations, access to academic research, and a skilled talent pool. It also provides a professional and credible base for its operations.
While headquartered in the United Kingdom, Destiny Pharma's operational reach is global, primarily through the management of international clinical trials for its drug candidates. The company collaborates with research institutions and Clinical Research Organizations (CROs) in various countries to advance its pipeline. Its product candidates, if successful, target global healthcare markets, particularly in regions with high rates of hospital-acquired infections and antimicrobial resistance.
Sussex Innovation Centre, Science Park Square
Brighton
East Sussex
United Kingdom
Address: Destiny Pharma primarily operates from its UK headquarters. Specific project-based or collaborator sites may exist but are not listed as formal secondary offices.
Global clinical trial execution and potential future commercial partnerships would necessitate international engagement, but not necessarily permanent office locations at this stage.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Destiny Pharma Limited - In Administration' leadership includes:
Destiny Pharma Limited - In Administration has been backed by several prominent investors over the years, including:
Destiny Pharma has seen significant strengthening of its executive team over the past 12-18 months, including a new CEO and CMO, and a transition in the CFO role, positioning the company for its next phase of clinical development and strategic growth.
Discover the tools Destiny Pharma Limited - In Administration uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
The most common email format for Destiny Pharma Ltd. appears to use the first initial followed by the last name.
[first_initial][last]@destinypharma.com
Format
ctovey@destinypharma.com
Example
90%
Success rate
Proactive Investors • 2024-05-28
Destiny Pharma is set for a pivotal Phase III study of its XF-73 Nasal Gel following encouraging Phase IIb results. The trial design is agreed with the FDA, and the company is exploring non-dilutive funding options....more
Destiny Pharma PLC • 2024-04-29
Destiny Pharma reported positive top-line results from its XF-73 Nasal Phase 2b clinical study. The study met its primary endpoint, showing a statistically significant reduction in S. aureus colonisation in the treated group....more
ShareCast • 2024-01-18
Destiny Pharma has appointed Dr. Yuri Martina as its new chief medical officer, effective from 18 January. Dr. Martina brings extensive experience in clinical development and medical affairs in the pharmaceutical industry....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Destiny Pharma Limited - In Administration, are just a search away.